Poseltinib is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Autoimmune Disorders. According to GlobalData, Phase II drugs for Autoimmune Disorders have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Poseltinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Poseltinib overview
Poseltinib (HM-71224) is under development for the treatment of autoimmune diseases including systemic lupus erythematosus, diffuse large b-cell lymphoma and follicular lymphoma. The drug candidate is administered through oral route. The drug candidate is a new chemical entity (NCE) targeting Bruton’s tyrosine kinase (BTK). It is based on NCE (new chemical entities) discovery technology. The drug candidate was under development for the treatment of rheumatoid arthritis, allergic diseases and other immunological disorders.
Hanmi Pharmaceuticals overview
Hanmi Pharmaceuticals, a subsidiary of Hanmi Science Co Ltd, develops prescription drugs and over the counter (OTC) drugs. The company’s prescription drugs include antibiotics, antidiarrheal, drugs for osteoporosis, liver supplements, and antiemetics. It provides OTC products such as nutritional supplements, calcium supplement, and vitamins, among others. The products of Hanmi Pharmaceuticals are used in the treatment of cancer, depression, dementia, dermatology, diabetes, inflammation, cardiovascular conditions, epilepsy, hepatitis, osteoarthritis, gastrointestinal diseases, obesity, osteoporosis, and others. The company operates manufacturing facilities in Hwaseong, Songpa and Pyeongtaek, South Korea. It supplies its products and APIs in various countries in Europe, Asia-Pacific, and the Americas. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.
For a complete picture of Poseltinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
